{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"7.2"},{"groupId":"OG001","spread":"1.0","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Sleepiness as measured by the Epworth Sleep Scale. It consists of 8 questions that measure daytime sleepiness in which the patient records their likelihood of dozing or sleeping during a number of routine daily activities. ESS scores range from 0 to 24. Higher scores denote greater sleepiness.","dispersionType":"Standard Error","groups":[{"description":"Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nArmodafinil: Given orally","id":"OG000","title":"Arm I - Armodafinil"},{"description":"Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nplacebo: Given orally","id":"OG001","title":"Arm II - Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Participants with any data","reportingStatus":"POSTED","timeFrame":"4 weeks post-RT","title":"Sleepiness","type":"SECONDARY","unitOfMeasure":"units on a scale"}